CD11D抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD11D mouse mAb (green) and negative control (red).    

  
  

CD11D antibody targets the CD11d integrin subunit, a member of the β2-integrin family. CD11d pairs noncovalently with CD18 to form the αDβ2 integrin (CD11d/CD18), primarily expressed on subsets of leukocytes, including monocytes, macrophages, and activated lymphocytes. Unlike other β2-integrins (e.g., CD11a, CD11b), CD11d exhibits distinct ligand-binding properties, interacting with vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-3 (ICAM-3), and extracellular matrix components. This integrin mediates leukocyte adhesion, migration, and activation in inflammatory and immune responses, particularly in chronic or non-resolving inflammatory conditions.

CD11d is implicated in pathologies such as atherosclerosis, multiple sclerosis, and ischemic stroke, where its overexpression enhances leukocyte infiltration into tissues. Research using CD11d antibodies has highlighted its role in modulating immune cell trafficking and inflammation in preclinical models. For instance, blocking CD11d/CD18 with specific antibodies reduces neuroinflammation and tissue damage in experimental autoimmune encephalomyelitis (EAE) and stroke models. These antibodies are valuable tools for studying integrin-mediated signaling pathways and validating therapeutic targets. Despite its lower profile compared to other β2-integrins, CD11d's unique expression patterns and ligand interactions make it a focus for developing targeted therapies against inflammatory diseases. Current challenges include optimizing antibody specificity and understanding context-dependent roles in different disease microenvironments.